Article
Cardiac & Cardiovascular Systems
Benjamin E. Peterson, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean-Claude Tardif, Subodh Verma, Christie M. Ballantyne
Summary: Icosapent ethyl reduces the need for coronary revascularizations in patients with elevated triglycerides and increased cardiovascular risk who are receiving statin therapy, showing significant reduction in first and subsequent revascularizations as well as coronary artery bypass grafting.
Review
Pharmacology & Pharmacy
Manan Pareek, R. Preston Mason, Deepak L. Bhatt
Summary: In high cardiovascular risk patients, residual hypertriglyceridemia remains a significant contributor to elevated event rates despite traditional lipid-lowering therapy. Icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid, has been shown to effectively reduce cardiovascular events in these patients, especially when triglyceride levels remain high despite statin treatment. Omega-3 fatty acid preparations containing a mix of eicosapentaenoic acid and docosahexaenoic acid are not recommended for reducing cardiovascular risk.
EXPERT OPINION ON DRUG SAFETY
(2022)
Article
Cardiac & Cardiovascular Systems
Arjun Majithia, Deepak L. Bhatt, Allon N. Friedman, Michael Miller, Ph Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, Matthew Budoff, R. Preston Mason, Jean-Claude Tardif, William E. Boden, Christie M. Ballantyne
Summary: In the REDUCE-IT trial, icosapent ethyl reduced fatal and nonfatal ischemic events across a broad range of baseline eGFR categories.
Article
Cardiac & Cardiovascular Systems
Senthil Selvaraj, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Rebecca A. Juliano, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne
Summary: This study aimed to investigate the treatment effects of icosapent ethyl in patients with heart failure (HF). The results showed that icosapent ethyl reduced triglyceride and hs-CRP levels in patients with HF, and had similar cardiovascular risk reduction effects.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Review
Cardiac & Cardiovascular Systems
Peter P. Toth, Jean Ferrieres, Max Waters, Martin Bodtker Mortensen, Nick S. R. Lan, Nathan D. Wong
Summary: This review summarizes the eligibility and cost effectiveness studies of IPE conducted to date. Sixteen studies with 2,068,111 patients in primary or secondary prevention settings worldwide were included. The proportion of patients eligible for IPE ranged from 15% to 45%, depending on the selection criteria and population studied. Overall, eight cost-effectiveness studies from the US, Canada, Germany, Israel, and Australia indicated that IPE is particularly cost effective in patients with established CVD.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Prakriti Gaba, Deepak L. Bhatt, R. Preston Mason, Michael Miller, Subodh Verma, Ph Gabriel Steg, William E. Boden
Summary: This article reviews the key findings of the REDUCE-IT trial and its subsequent analyses, highlighting the efficacy of IPE in high-risk cardiovascular patients, and calls for its inclusion in current guidelines.
JOURNAL OF CLINICAL LIPIDOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Brian Olshansky, Deepak L. L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. A. Brinton, Terry A. A. Jacobson, Steven B. B. Ketchum, Ralph T. T. Doyle Jr, Rebecca A. A. Juliano, Lixia Jiao, Peter R. R. Kowey, James A. A. Reiffel, Jean-Claude Tardif, Christie M. M. Ballantyne, Mina K. K. Chung
Summary: In the REDUCE-IT study, icosapent ethyl (IPE) reduced cardiovascular events but was associated with increased atrial fibrillation/atrial flutter (AF) hospitalization. The study analyzed the relationships between IPE and outcomes in patients with or without prior AF and with or without in-study AF hospitalization. Overall, in-study AF hospitalization rates were higher in patients with prior AF, especially in those randomized to IPE. Serious bleeding rates also trended higher in these patients. However, patients with prior AF or in-study AF hospitalization showed consistent risk reductions in cardiovascular events with IPE.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Review
Pharmacology & Pharmacy
M. John Chapman, Jose L. Zamorano, Klaus G. Parhofer
Summary: Atherosclerotic cardiovascular disease (ASCVD) imposes a significant burden on Europe, and hypertriglyceridemia is a major risk factor for premature ASCVD. Recent studies have shown a correlation between elevated triglyceride levels and subclinical atherosclerosis and arterial inflammation. Icosapent ethyl (IPE) is a drug that can reduce the risk of cardiovascular events in patients with high triglyceride levels, possibly through triglyceride reduction and improvement of vascular function.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Medicine, General & Internal
Ashish Gupta, Mohammad Alkhalil
Summary: Omega-3 polyunsaturated fatty acids (PUFAs) have been established as a therapeutic option for patients with high triglyceride levels. They have effects on lipoprotein particles and can be incorporated within the cellular membrane, leading to plaque stability and anti-inflammatory effects. However, recent clinical trials have shown inconsistent results regarding the cardioprotective effects of omega-3 fatty acids.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Benjamin E. Peterson, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean-Claude Tardif, Subodh Verma, Christie M. Ballantyne
Summary: Icosapent Ethyl significantly reduces the risk of recurrent cardiovascular events in patients with elevated triglycerides and a history of prior percutaneous coronary intervention.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Review
Cardiac & Cardiovascular Systems
Jessica Huston, Hannah Schaffner, Alyssa Cox, Alexander Sperry, Shelby Mcgee, Payeng Lor, Logan Langley, Blake Skrable, Majdi Ashchi, Mohannad Bisharat, Ashwini Gore, Thomas Jones, David Sutton, Mae Sheikh-Ali, Jason Berner, Rebecca Goldfaden
Summary: Icosapent ethyl (IPE) is the first fish oil product approved by the US FDA to reduce the risk of ASCVD in adults. It acts as a prodrug in the body and primarily reduces TG levels. Various studies and subanalyses have investigated the effects of IPE, including its impact on different patient groups and inflammatory biomarkers. This article critically reviews the clinical data on the cardiovascular benefits of IPE in ASCVD patients and its value as a treatment option for elevated TG levels.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
(2023)
Article
Cardiac & Cardiovascular Systems
Subodh Verma, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Nitish K. Dhingra, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, R. Preston Mason, Jean-Claude Tardif, Christie M. Ballantyne
Summary: In patients with a history of coronary artery bypass grafting, treatment with icosapent ethyl in the REDUCE-IT trial led to significant reductions in both first and recurrent ischemic events compared to placebo, with similar safety findings between groups.
Review
Medicine, General & Internal
Kamini Trivedi, Viet Le, John R. Nelson
Summary: The FDA recently approved high-purity IPE, a prescription fish oil-derived omega-3 fatty acid, for CVD prevention in high-risk patients based on the 25% reduction in CVD event risk observed in the REDUCE-IT trial. IPE, compared to mixed omega-3 products, has shown to be a stable, highly purified formulation with FDA approval, making it an effective choice for CV prevention.
POSTGRADUATE MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Ailing Ji, Andrea C. Trumbauer, Victoria P. Noffsinger, Frederick C. de Beer, Nancy R. Webb, Lisa R. Tannock, Preetha Shridas
Summary: Serum amyloid A (SAA) is predictive of cardiovascular disease (CVD) in humans and induces atherosclerosis in mice. However, the proatherogenic effects of SAA are masked by high-density lipoprotein (HDL), the major carrier of SAA. Cholesteryl ester transfer protein (CETP) remodels HDL, releasing SAA and restoring its proinflammatory activity. Inhibiting CETP may therefore benefit patients with high SAA levels.
JOURNAL OF LIPID RESEARCH
(2023)
Review
Cardiac & Cardiovascular Systems
Ronald M. Goldenberg, Alice Y. Y. Cheng, Jeremy D. Gilbert, Eva M. Lonn, Sue D. Pedersen, Subodh Verma
Summary: High triglyceride levels are associated with heightened cardiovascular risk, despite LDL-C levels and statin therapy. The REDUCE-IT trial with IPE demonstrated reduced cardiovascular risk in individuals with preexisting atherosclerotic cardiovascular disease or diabetes.
CURRENT OPINION IN CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Amit Saha, Kershaw Patel, Colby Ayers, Christie M. Ballantyne, Adolfo Correa, Christopher Defilippi, Michael E. Hall, Robert J. Mentz, Stephen L. Seliger, Wondwosen Yimer, Javed Butler, Jarett D. Berry, James A. De Lemos, Ambarish Pandey
Summary: Among Black adults, persistent or worsening levels of cardiac troponin I (hs-cTnI) are associated with an increased risk of heart failure (HF). Participants with incident, stable or improved, or worsened hs-cTnI elevation had higher HF risk compared to those without elevated hs-cTnI.
JOURNAL OF CARDIAC FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Michael Miller, Deepak L. Bhatt, Ph Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne, Matthew Budoff, R. Preston Mason
Summary: The study found that the use of IPE can reduce the risk of cardiovascular disease in smokers to the level observed in non-smokers.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Peripheral Vascular Disease
Matthew F. Blum, Jingsha Chen, Aditya Surapaneni, Stephen T. Turner, Christie M. Ballantyne, Paul A. Welling, Anna Koettgen, Josef Coresh, Deidra C. Crews, Morgan E. Grams
Summary: This study investigated the association of renin with adverse kidney outcomes and compared different measurement strategies. The results showed that renin levels measured by SomaScan modified nucleotide aptamer assay were predictive of chronic kidney disease, end-stage kidney disease, and mortality. The SomaScan measurement was moderately correlated with plasma renin activity and highly correlated with renin level from Olink.
AMERICAN JOURNAL OF HYPERTENSION
(2023)
Article
Urology & Nephrology
Donghai Wen, Linda Zhou, Zihe Zheng, Aditya Surapaneni, Christie M. Ballantyne, Ron C. Hoogeveen, Michael G. Shlipak, Sushrut S. Waikar, Ramachandran S. Vasan, Paul L. Kimmel, Ruth F. Dubin, Rajat Deo, Harold I. Feldman, Peter Ganz, Josef Coresh, Morgan E. Grams, Eugene P. Rhee
Summary: Testican-2, a protein released into circulation by the kidneys, is positively correlated with eGFR and eGFR slope. However, it is unknown whether higher testican-2 levels are associated with lower risk of ESKD.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Review
Medical Laboratory Technology
Seyedmohammad Saadatagah, Christie M. Ballantyne
Summary: Age is a crucial risk factor for cardiovascular disease, as genetic mutations occur with aging, leading to somatic mosaicism. Clonal hematopoiesis resulting from somatic mutations, known as CHIP, has been associated with an increased risk of cardiovascular disease. Recent advances in exome-sequencing projects have enabled the study of CHIP frequency, gene-specific analyses, and potential therapeutic implications for preventing cardiovascular disease.
TRANSLATIONAL RESEARCH
(2023)
Article
Medical Laboratory Technology
Mary R. Rooney, Jingsha Chen, Christie M. Ballantyne, Ron C. Hoogeveen, Olive Tang, Morgan E. Grams, Adrienne Tin, Chiadi E. Ndumele, Faiez Zannad, David J. Couper, Weihong Tang, Elizabeth Selvin, Josef Coresh
Summary: Comparisons of highly multiplexed aptamer-based and proximity-extension immunoassays revealed variations in protein measurements. Furthermore, comparisons between SomaScan and targeted immunoassays showed varying degrees of correlation for different proteins. These findings highlight the importance of considering measurement techniques in protein quantification studies.
CLINICAL CHEMISTRY
(2023)
Article
Pharmacology & Pharmacy
Anandita Agarwala, Elena Deych, Laney K. Jones, Amy C. Sturm, Karen Aspry, Zahid Ahmad, Christie M. Ballantyne, Anne C. Goldberg
Summary: This study retrospectively examined the burden and risk factors of premature ASCVD in men and women with FH. The results showed a high prevalence of premature ASCVD in both genders, and significant differences were observed in predictive factors and lipid treatment outcomes for women with premature ASCVD.
JOURNAL OF CLINICAL LIPIDOLOGY
(2023)
Article
Pharmacology & Pharmacy
Mini G. Varughese, Matthew R. Deshotels, Lilei Zhang, Christie M. Ballantyne
Summary: A 20-year-old male presented with severe elevation in low-density lipoprotein cholesterol (LDL-C) and was initially tested negative for familial hypercholesterolemia. Further genetic testing revealed homozygous variants in the ALB gene, indicating congenital analbuminemia (CAA) as the cause of severe hyperlipidemia. CAA is a rare autosomal recessive disorder with a frequency of about 1:1,000,000. Pathological variants in the ALB gene disrupt albumin synthesis and can lead to gross hyperlipidemia and hypercholesterolemia. Early diagnosis through genetic examination is crucial for initiating lipid-lowering treatments and preventing premature coronary artery disease.
JOURNAL OF CLINICAL LIPIDOLOGY
(2023)
Article
Biochemical Research Methods
Bruno Bohn, Pamela L. Lutsey, Weihong Tang, James S. Pankow, Faye L. Norby, Bing Yu, Christie M. Ballantyne, Eric A. Whitsel, Kunihiro Matsushita, Ryan T. Demmer
Summary: This study compared the proteome of statin users and nonusers and found differences in proteins unrelated to lipid metabolism. Further investigation into these differences may help elucidate the pleiotropic effects of statins.
JOURNAL OF PROTEOMICS
(2023)
Letter
Cardiac & Cardiovascular Systems
Salim S. S. Virani, David J. J. Ramsey, Dax Westerman, Mark K. K. Kuebeler, Liang Chen, Julia M. M. Akeroyd, Glenn T. T. Gobbel, Christie M. M. Ballantyne, Laura A. A. Petersen, Alexander Turchin, Michael E. E. Matheny
Letter
Cardiac & Cardiovascular Systems
Yiyi Zhang, Jacqueline S. Dron, Brandon K. Bellows, Amit V. Khera, Junxiu Liu, Pallavi P. Balte, Elizabeth C. Oelsner, Sami Samir Amr, Matthew S. Lebo, Anna Nagy, Gina M. Peloso, Pradeep Natarajan, Jerome I. Rotter, Cristen Willer, Eric Boerwinkle, Christie M. Ballantyne, Pamela L. Lutsey, Myriam Fornage, Donald M. Lloyd-Jones, Lifang Hou, Bruce M. Psaty, Joshua C. Bis, James S. Floyd, Ramachandran S. Vasan, Nancy L. Heard-Costa, April P. Carson, Michael E. Hall, Stephen S. Rich, Xiuqing Guo, Dhruv S. Kazi, Sarah D. de Ferranti, Andrew E. Moran
Article
Cardiac & Cardiovascular Systems
Nicolas Girerd, Daniel Levy, Kevin Duarte, Joao Pedro Ferreira, Christie Ballantyne, Timothy Collier, Anne Pizard, Jens Bjoerkman, Javed Butler, Andrew Clark, John G. Cleland, Christian Delles, Javier Diez, Arantxa Gonzalez, Mark Hazebroek, Jennifer Ho, Anne-Cecile Huby, Shih-Jen Hwang, Roberto Latini, Beatrice Mariottoni, Alexandre Mebazaa, Pierpaolo Pellicori, Naveed Sattar, Peter Sever, Jan A. Staessen, Job Verdonschot, Stephane Heymans, Patrick Rossignol, Faiez Zannad
Summary: This study identified protein biomarkers associated with new-onset heart failure in three independent cohorts. The inclusion of these biomarkers in addition to clinical risk factors improved the prediction of heart failure risk. The B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide were found to be particularly relevant in predicting heart failure.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Xiaoming Jia, Leo Buckley, Caroline Sun, Mahmoud Al Rifai, Bing Yu, Vijay Nambi, Salim S. Virani, Elizabeth Selvin, Kunihiro Matsushita, Ron C. Hoogeveen, Josef Coresh, Amil M. Shah, Christie M. Ballantyne
Summary: Higher levels of interleukin-6 and interleukin-18 in older adults are associated with an increased risk of global cardiovascular disease (including coronary heart disease, stroke, and heart failure) and death. The association between interleukin-6 and global cardiovascular disease is stronger than that for interleukin-18, and remains significant even after adjustments for other biomarkers.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Lena Mathews, Xiao Hu, Ning Ding, Junichi Ishigami, Mahmoud Al Rifai, Ron C. C. Hoogeveen, Josef Coresh, Christie M. M. Ballantyne, Elizabeth Selvin, Kunihiro Matsushita
Summary: A study on 9205 participants from the ARIC study found that higher levels of GDF15 protein were associated with bleeding events and improved the prediction of bleeding risk in individuals without cardiovascular disease.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Marina Cuchel, Paul C. Lee, Lisa C. Hudgins, P. Barton Duell, Zahid Ahmad, Seth J. Baum, MacRae F. Linton, Sarah D. de Ferranti, Christie M. Ballantyne, John A. Larry, Linda C. Hemphill, Iris Kindt, Samuel S. Gidding, Seth S. Martin, Patrick M. Moriarty, Paul P. Thompson, James A. Underberg, John R. Guyton, Rolf L. Andersen, David J. Whellan, Irwin Benuck, John P. Kane, Kelly Myers, William Howard, David Staszak, Allison Jamison, Mary C. Card, Mafalda Bourbon, Joana R. Chora, Daniel J. Rader, Joshua W. Knowles, Katherine Wilemon, Mary P. McGowan
Summary: This study investigated the diagnosis and treatment of HoFH in the United States and found a low diagnosis rate and low treatment rate, highlighting the need for enhanced screening and treatment to reduce the burden of the disease.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Jose E. Exaire, Timothy A. Mixon
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Giuseppe Di Gioia, Federica Coletti, Lorenzo Buzzelli, Viviana Maestrini, Sara Monosilio, Andrea Segreti, Maria Rosaria Squeo, Erika Lemme, Antonio Nenna, Antonio Pelliccia
Summary: Dyslipidemia is common in Paralympic athletes, with lipid levels influenced by the type of disability and sporting discipline.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Esra Donmez, Sevgi Ozcan, Irfan Sahin, Murat Ziyrek, Ertugrul Okuyan
Summary: This study aimed to evaluate the predictive value of the GRACE risk score in acute pulmonary embolism (PE) patients for 30-day mortality and the need for thrombolytic treatment. The study found that the GRACE risk score, along with the PESI score, were independent risk factors associated with 30-day mortality and the need for thrombolytic treatment. The GRACE risk score showed high sensitivity and specificity in predicting mortality, and its combination with the PESI score helped define high-risk PE patients and predict poor prognosis.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Tom Kai Ming Wang, Reza Reyaldeen, Kevser Akyuz, Zoran B. Popovic, A. Marc Gillinov, Bo Xu, Brian P. Griffin, Milind Y. Desai
Summary: Transthoracic echocardiography (TTE) is commonly used to evaluate isolated tricuspid regurgitation (TR), but there is limited research comparing its quantification with magnetic resonance imaging (MRI). In this study, a novel TTE algorithm was developed to identify severe TR based on TTE parameters. The algorithm had a higher accuracy than the current guidelines' criteria in detecting severe TR by MRI.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Editorial Material
Cardiac & Cardiovascular Systems
Enkhtsogt Sainbayar, Ramzi Ibrahim, Hoang Nhat Pham, Wisam Beauti, Mahek Shahid, Natalie Hickerson, Mohammed Salih, Joao Paulo Ferreira, Mamas A. Mamas
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Richard E. Casazza, Hymie Chera, Carlos Adolfo Rodriguez, Sergey Ayzenberg
Summary: This article presents a case of a patient with known situs inversus who underwent cardiac catheterization and was found to have chronic total occlusion in the right coronary artery. Situs inversus is a rare congenital abnormality characterized by the inverted position of chest and abdominal organs. Cardiac catheterization is uncommon in patients with this particular abnormality, highlighting the importance of customizing techniques to engage coronary arteries and optimize guide support for percutaneous coronary intervention if needed.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Editorial Material
Cardiac & Cardiovascular Systems
Georgiana Pintea Bentea, Brahim Berdaoui, Sophie Samyn, Marielle Morissens, Philippe van de Borne, Jose Castro Rodriguez
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Bulbul Ahmed, Melissa G. Farb, Shakun Karki, Sophia D'Alessandro, Niloo M. Edwards, Noyan Gokce
Summary: This study evaluated the angiogenic capacity of adipose tissue in patients undergoing cardiac surgeries and found that patients with coronary artery disease (CAD) had reduced angiogenic capacity in their pericardial adipose tissue. Gene expression analysis revealed upregulated expression of the anti-angiogenic gene TSP-1 in CAD patients, with no significant differences in other angiogenic factors. Additionally, inhibiting TSP-1 expression significantly improved angiogenic deficiency in CAD patients.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Moshe Rav-Acha, Orli Wube, Oholi Tovia Brodie, Yoav Michowitz, Michael Ilan, Tal Ovdat, Robert Klempfner, Mahmud Suleiman, Ilan Goldenberg, Michael Glikson
Summary: The current guidelines recommend prophylactic implantable cardioverter-defibrillator (ICD) for patients with symptomatic heart failure (HF) and low left ventricular ejection fraction. However, not all patients will benefit from ICD treatment. This study evaluated the feasibility of using the MADIT-II-based Risk Stratification Score (MRSS) to predict the survival benefit of prophylactic ICDs in patients with HF. The results showed that different risk subgroups had varying levels of ICD survival benefit.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Ariel Banai, Rachel Retsky, Lior Lupu, Erez Levi, David Zahler, Omri Feder, Roei Merin, Yan Topilsky, Raphael Rosso, Shmuel Banai, Sami Viskin, Ehud Chorin
Summary: This study aims to evaluate the association between electromechanical window (EMW) and ventricular tachyarrhythmias in patients with Takotsubo syndrome (TTS). The study found that TTS patients had a lower EMW value, which was associated with an increased risk of ventricular tachyarrhythmias.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Harun Kundi, Kobina Hagan, Tamer Yahya, Garima Sharma, Sadeer Al-Kindi, Zulqarnain Javed, Khurram Nasir
Summary: Using latent class analysis (LCA), the study identified clinical, demographic, and social subphenotypes in ASCVD population and assessed the risk of all-cause and cardiovascular mortality across different socioclinical classes. The results showed that the younger, female, non-Hispanic Black or Hispanic individuals with a high burden of co-morbidities and unfavorable social determinants of health had the highest risk of mortality in the identified latent classes.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Moises A. Vasquez, Mina Iskander, Mohammed Mustafa, Juan A. Quintero-Martinez, Antonio Luna, Joel Mintz, Jose Noy, Juan Uribe, Ivan Mijares, Eduardo de Marchena, Yiannis S. Chatzizisis
Summary: The benefits of pericardiocentesis (PC) in patients with pulmonary hypertension (PH) and pericardial effusions are unclear. The study found that PC in PH patients is associated with higher in-hospital mortality and rates of cardiovascular complications.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Ken Kuwajima, Mana Ogawa, Irving Ruiz, Hiroko Hasegawa, Nobuichiro Yagi, Florian Rader, Robert J. Siegel, Takahiro Shiota
Summary: After cardiac surgery, the longitudinal function of the right ventricle and left ventricle is reduced, despite preserved global functions. In particular, tricuspid annular plane systolic excursion (TAPSE) remains decreased after surgery.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Min -Jung Kim, Robert H. Aseltine Jr, Sara R. Tabtabai
Summary: This study evaluated the rates and causes of 30-day readmissions after discharge for heart failure (HF) as a primary and secondary diagnosis. The findings indicate that efforts to reduce readmission rates should include patients with secondary HF diagnosis, and surveillance should extend to 2 weeks postdischarge to identify at-risk patients.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Ya He, Jianzhong Zhou
Summary: This study aimed to examine the relation between reverse septal curvature (RSC) and nonsustained ventricular tachycardia (NSVT) in patients with hypertrophic cardiomyopathy (HCM). The study found that patients with RSC were younger and had a higher incidence of NSVT, and RSC was identified as a strong independent risk factor for NSVT.
AMERICAN JOURNAL OF CARDIOLOGY
(2024)